Monotherapy Is Dead: Why ADCs and PD-1 Checkpoint Inhibitors Are the New Standard for SCLC and NSCLC
The global oncology landscape is undergoing a seismic shift. For the past decade, immune checkpoint inhibitors targeting the PD-1 and PD-L1 pathways have been the undisputed titans of cancer care. Heavyweights like Merck’s Keytruda have rewritten the survival curves for millions. However, as monotherapy reaches its therapeutic ceiling—particularly in aggressive, “cold” microenvironments—the biopharma industry is … Read more